Meeting
2023 ASCO Genitourinary Cancers Symposium
A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Daniel P. Petrylak
Smilow Cancer Center, Yale School of Medicine, New Haven, CT
Daniel P. Petrylak , Tyler F. Stewart , Xin Gao , Elmer Berghorn , Haolan Lu , Edward Chan , Richard Gedrich , Joshua Michael Lang , Meredith McKean
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05067140
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS290)
DOI
10.1200/JCO.2023.41.6_suppl.TPS290
Abstract #
TPS290
Poster Bd #
Q12
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 1b study of bavdegalutamide, an androgen receptor PROTAC degrader, combined with abiraterone in patients with metastatic prostate cancer.
First Author: Neal D. Shore
Poster
2022 ASCO Genitourinary Cancers Symposium
ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
First Author: Louise Emmett
Poster
2021 Genitourinary Cancers Symposium
ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
First Author: Louise Emmett
Poster
2020 Genitourinary Cancers Symposium
Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC).
First Author: Anthony Serritella